Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Judith Feinberg; Karen Tashima; Robert L Murphy; Margaret A Fischl; AIDS Clinical Trials Group Study

doi:10.1093/infdis/jir505

Back

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

Journal article

Open access

Peer reviewed

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

Paul E Sax, Camlin Tierney, Ann C Collier, Eric S Daar, Katie Mollan, Chakra Budhathoki, Catherine Godfrey, Nasreen C Jahed, Laurie Myers, David Katzenstein, …

The Journal of infectious diseases, Vol.204(8), pp.1191-1201

10/15/2011

DOI: 10.1093/infdis/jir505

PMCID: PMC3173503

PMID: 21917892

Files and links (1)

url

https://doi.org/10.1093/infdis/jir505View

Published (Version of record) Open Access

Abstract

(See the editorial commentary by Hull and Montaner, on pages 1154–6 .) Background. AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening HIV RNA (< or ≥10 5 copies/mL). Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients. Methods. Primary endpoints were times to virologic failure, regimen modification, and safety event. Results. In the low HIV RNA stratum, time to virologic failure was similar for ABC/3TC vs TDF/FTC with ATV/r (hazard ratio [HR] 1.25, 95% confidence interval [CI] 0.76, 2.05) or EFV (HR 1.23, 95% CI 0.77, 1.96), with significantly shorter times to regimen modification for ABC/3TC with EFV or ATV/r and to safety events with EFV. Prior to stopping blinded treatment in the high stratum, higher virologic failure rates were seen with ABC/3TC with EFV (HR 2.46, 95% CI 1.20, 5.05) or ATV/r (HR 2.22, 95% CI 1.19, 4.14). Conclusions. In the low HIV RNA stratum, times to virologic failure for ABC/3TC or TDF/FTC were not different with EFV or ATV/r. In the high stratum, virologic failure rate was significantly higher for ABC/3TC than for TDF/FTC when given with either EFV or ATV/r.

Major and Brief Reports

Details

Title: Subtitle: Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results
Creators: Paul E Sax - Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, and
Camlin Tierney - Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
Ann C Collier - University of Washington School of Medicine, Harborview Medical Center, Seattle
Eric S Daar - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, the University of California
Katie Mollan - Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
Chakra Budhathoki - Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
Catherine Godfrey - The Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Nasreen C Jahed - Social & Scientific Systems, Inc., Silver Spring, Maryland
Laurie Myers - Frontier Science & Technology Research Foundation, Amherst, New York
David Katzenstein - Stanford University, Palo Alto, California
Awny Farajallah - Bristol-Myers Squibb, Plainsboro, New Jersey
James F Rooney - Gilead Sciences, Foster City, California
Belinda Ha - GlaxoSmithKline, Research Triangle Park, North Carolina
William C Woodward - Abbott Laboratories, Illinois
Judith Feinberg - University of Cincinnati, Cincinnati, Ohio
Karen Tashima - Brown University, Providence, Rhode Island
Robert L Murphy - Northwestern University, Chicago, Illinois
Margaret A Fischl - University of Miami School of Medicine, Florida
AIDS Clinical Trials Group Study
Contributors: Jeffery L Meier (Contributor) - University of Iowa, Internal Medicine
Jack T Stapleton (Contributor) - University of Iowa, Internal Medicine
Resource Type: Journal article
Publication Details: The Journal of infectious diseases, Vol.204(8), pp.1191-1201
DOI: 10.1093/infdis/jir505
PMID: 21917892
PMCID: PMC3173503
NLM abbreviation: J Infect Dis
ISSN: 0022-1899
eISSN: 1537-6613
Publisher: Oxford University Press
Language: English
Date published: 10/15/2011
Academic Unit: Microbiology and Immunology; Infectious Diseases; Epidemiology; Internal Medicine
Record Identifier: 9984094330802771

Metrics

27 Record Views

150 Times Cited - Web of Science